Browsing Tag
Corvidia Therapeutics Inc.
1 post
Novo Nordisk’s $2.1bn Corvidia bet faces impairment after ZEUS trial miss
Ziltivekimab’s Phase 3 failure sends Novo Nordisk down 9%, triggers a Corvidia impairment and weakens its cardiovascular expansion strategy.